secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001628280-22-028167
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics Q3 net loss $53.2M; revenue down, Fabry gene therapy expands
--------------------------------------------------------------------------------

- Q3 net loss $53.2M ($0.34/shr) vs $47.7M ($0.33/shr) prior year; revenue $26.5M down from $28.6M.
- Cash $350.3M at Sep 30 (Dec 31: $464.7M); raised $75.1M net from ATM Jan-Oct 2022.
- FY2022 guidance narrowed: GAAP op expenses $315-325M, non-GAAP $280-290M (excl ~$35M SBC).
- Fabry gene therapy STAAR expansion: 5 patients dosed at 5e13 vg/kg, including first two females; Phase 3 prep ongoing.
- Hemophilia A (Pfizer) Phase 3 AFFINE trial recruitment resumed; pivotal readout expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828022028167/0001628280-22-028167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828022028167/sgmo-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer